FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
REDWOOD CITY, Calif., March 27, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development. Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research. In this position, Mr. Wiberg will be responsible for product licensing, corporate strategy, as well as M&A.
“We are very gratified to have a corporate development professional of Mr. Wiberg’s caliber choose to join the Coherus team,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “2017 is a transformational year for Coherus, as we prepare our first product approval. Erik’s proven track record of execution within corporate development will be critical to effectively achieving our business objectives.”
Mr. Wiberg has extensive experience in corporate development, completing numerous out-licensing, in-licensing, merger and acquisition, and financing transactions and research & development collaborations that achieved corporate priorities and created significant value for shareholders at ALZA Corporation, Johnson & Johnson, Anacor Pharmaceuticals, Inc., and Catalyst Biosciences, Inc. Erik was most recently Senior Vice President, Strategy and Corporate Development at Anacor Pharmaceuticals, Inc. a company acquired by Pfizer in 2016 for $5.2 billion. He has also held leadership positions in corporate strategy, new product planning and portfolio management. Erik earned his dual degree in business and engineering from University of Pennsylvania, where he attended the Wharton School of Business and earned his Bachelor of Science in Economics, dual major in Finance and Accounting, and the School of Engineering and Applied Science where he earned his Bachelor of Applied Science with a major in Computer Science Engineering.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, expectations, goals, objectives, strategies, product pipeline, clinical studies, product development, and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to effectively achieve our business objectives. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2016 and its subsequent periodic reports filed with the SEC.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
